Pages that link to "Q45504141"
Jump to navigation
Jump to search
The following pages link to Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants (Q45504141):
Displaying 50 items.
- Vaccines for the common cold (Q24201977) (← links)
- Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease (Q26775152) (← links)
- Development of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genes (Q26782411) (← links)
- Quantification and determinants of the amount of respiratory syncytial virus (RSV) shed using real time PCR data from a longitudinal household study (Q28365074) (← links)
- Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis (Q29619821) (← links)
- Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. (Q30363581) (← links)
- Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. (Q30485791) (← links)
- New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens (Q33508318) (← links)
- The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya (Q33596091) (← links)
- Recombinant bovine respiratory syncytial virus with deletion of the SH gene induces increased apoptosis and pro-inflammatory cytokines in vitro, and is attenuated and induces protective immunity in calves. (Q33635085) (← links)
- Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya. (Q33712986) (← links)
- Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys (Q33748766) (← links)
- Pharmacologic advances in the treatment and prevention of respiratory syncytial virus (Q33776507) (← links)
- Characterization of an experimental vaccine for bovine respiratory syncytial virus. (Q33899379) (← links)
- The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity (Q33930308) (← links)
- RNA virus reverse genetics and vaccine design. (Q33963398) (← links)
- Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro (Q33964142) (← links)
- Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates (Q33984333) (← links)
- Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates (Q34092801) (← links)
- Gene expression differences in lungs of mice during secondary immune responses to respiratory syncytial virus infection. (Q34120191) (← links)
- Progress in the development of human parainfluenza virus vaccines (Q34209872) (← links)
- Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo (Q34228628) (← links)
- New insights for development of a safe and protective RSV vaccine (Q34249859) (← links)
- Viral etiology of severe pneumonia among Kenyan infants and children. (Q34262582) (← links)
- Current concepts and progress in RSV vaccine development. (Q34396689) (← links)
- Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies (Q34425648) (← links)
- Ginseng diminishes lung disease in mice immunized with formalin-inactivated respiratory syncytial virus after challenge by modulating host immune responses (Q34440116) (← links)
- Biological challenges and technological opportunities for respiratory syncytial virus vaccine development (Q34504791) (← links)
- A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation (Q34547769) (← links)
- Attenuation of human respiratory syncytial virus by genome-scale codon-pair deoptimization (Q34583420) (← links)
- Methyltransferase-defective avian metapneumovirus vaccines provide complete protection against challenge with the homologous Colorado strain and the heterologous Minnesota strain. (Q34593654) (← links)
- Immunization strategies for the prevention of pneumovirus infections. (Q34615678) (← links)
- A comprehensive proteomic view of responses of A549 type II alveolar epithelial cells to human respiratory syncytial virus infection (Q34634867) (← links)
- TLR4 genotype and environmental LPS mediate RSV bronchiolitis through Th2 polarization (Q35056722) (← links)
- Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease (Q35070176) (← links)
- Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice (Q35077892) (← links)
- An overview of respiratory syncytial virus. (Q35157041) (← links)
- Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years (Q35566601) (← links)
- An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children (Q35595950) (← links)
- Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials (Q35761061) (← links)
- Vaccine Induced Herd Immunity for Control of Respiratory Syncytial Virus Disease in a Low-Income Country Setting (Q35781865) (← links)
- Mucosal inoculation with an attenuated mouse pneumovirus strain protects against virulent challenge in wild type and interferon-gamma receptor deficient mice. (Q35897408) (← links)
- Partial Attenuation of Respiratory Syncytial Virus with a Deletion of a Small Hydrophobic Gene Is Associated with Elevated Interleukin-1β Responses (Q35913930) (← links)
- Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels (Q35914345) (← links)
- Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins (Q35995788) (← links)
- Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains (Q36005114) (← links)
- Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates. (Q36088161) (← links)
- The human respiratory syncytial virus nonstructural protein 1 regulates type I and type II interferon pathways (Q36163501) (← links)
- New generation live vaccines against human respiratory syncytial virus designed by reverse genetics (Q36237057) (← links)
- Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phas (Q36258838) (← links)